The cardiovascular safety of smoking cessation pharmacotherapies

Image - The cardiovascular safety of smoking cessation pharmacotherapies
Date Published:
6 Sep 2018
Contact person:
NDARC reception +61 (2) 9385 0333
Event date: 
Thursday, 20 September 2018 - 3:00pm

The National Drug and Alcohol Research Centre is pleased to present:

Dr Alys Havard (Centre for Big Data Research in Health, UNSW)
“The cardiovascular safety of smoking cessation pharmacotherapies”

Thursday, 25 October 3.00pm-4.00pm

About the speaker:

Dr Alys Havard is a Senior Research Fellow in the Centre for Big Data Research in Health at the University of New South Wales (UNSW). Her primary research interest is in using linked administrative datasets for tobacco control research and for examining the utilisation and safety of prescription medications.

Dr Havard recently completed an NHMRC-funded Early Career Fellowship in which she examined the epidemiology of smoking and smoking cessation medications using data from the 45 and Up Study linked to health services data. She is currently undertaking a National Heart Foundation-funded Future Leader Fellowship in which she is examining the safety of smoking cessation medications in the general population, as well as methods for measuring depression from routinely collected health data. Dr Havard is also currently leading an NHMRC-funded project investigating the use, effectiveness and safety of smoking cessation medications prior to and during pregnancy, with a particular focus on Aboriginal women.

Open to: 
Public
Location: 
NDARC Seminar Room: Building R1, UNSW Australia Randwick Campus, 22 - 32 King Street, Randwick (visitors please report to reception in building R3)
Cost: 
Free - no booking required
Contact for inquiries: 
NDARC reception +61 (2) 9385 0333